Retatrutide

Overview

Retatrutide (development code LY3437943, Eli Lilly) is an investigational single-peptide ("unimolecular") compound designed to simultaneously activate three class B G-protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR) ^[1]. Owing to its simultaneous action on three targets, retatrutide belongs to the class of so-called "triple" (triagonist) incretin compounds, which conceptually extends the dual GIP/GLP-1 agonism strategy used in tirzepatide ^[1][3].

The molecule is a single peptide approximately 39 amino acid residues in length, built on a GIP peptide backbone, with a C-terminal serinamide (the terminal carboxyl replaced with a carboxamide) ^[1]. The molar mass of retatrutide is approximately 4731 Da. The compound's half-life in circulation is approximately 6 days, consistent with the once-weekly subcutaneous dosing interval used in studies ^[1][2]. In the research context, retatrutide is supplied as a lyophilized (freeze-dried) powder.

Retatrutide was characterized sequentially, from discovery and preclinical pharmacology through clinical proof of concept, in the work of Coskun et al. (Cell Metabolism, 2022) ^[1], after which the Phase 1 clinical pharmacology was described by Urva et al. (The Lancet, 2022) ^[2]. The subsequent Phase 2 program encompassed separate randomized trials in obesity ^[4], in type 2 diabetes mellitus ^[5], and in metabolic dysfunction-associated steatotic liver disease (MASLD) ^[7]. All data presented below describe the design and results of published preclinical and clinical studies; they do not constitute guidance for use.

Pharmacology and Mechanism of Action

Retatrutide acts as an agonist at three receptors, each involved in the regulation of energy and glucose metabolism. The mechanistic distinctiveness of the compound lies in the fact that a single peptide combines signaling pathways that were previously addressed by separate or dual agonists ^[1].

GIP Component

The molecule's backbone is derived from GIP, and it is to the GIP receptor that retatrutide shows the highest affinity. In cAMP accumulation assays in HEK293 cells expressing human receptors, the half-maximal effective concentration (EC50) of retatrutide was approximately 0.0643 nM for GIPR ^[1]. According to the primary source, this corresponds to a potency approximately 8.9-fold higher than that of native GIP at this receptor ^[1]. Thus, the compound's profile is skewed toward GIPR (GIPR-biased). Activation of GIPR together with GLP-1R, according to the authors' explanation, provides a reduction in caloric intake ^[1].

GLP-1 Component

Cross-reactivity with GLP-1R is achieved through targeted substitutions introduced into the GIP backbone ^[1]. For GLP-1R, the measured EC50 was approximately 0.775 nM ^[1]. The GLP-1 component contributes to reduced appetite and food intake, as well as to glycemic control, consistent with the known pharmacology of the GLP-1 agonist class ^[1][5].

Glucagon Component

Activity at the glucagon receptor (GCGR) was characterized by an EC50 of approximately 5.79 nM ^[1]. The primary source summarizes the in vitro profile as "balanced GCGR and GLP-1R activity with greater activity at GIPR", that is, a deliberately asymmetric rather than equipotent triagonism ^[1]. Mechanistically, it is the glucagon component that adds an "arm" of increased energy expenditure on top of the appetite suppression mediated by GIPR and GLP-1R; in the authors' view, the effect on body weight is an additive consequence of these components ^[1]. Glucagon signaling has historically been associated with increased blood glucose levels; however, in the triple-agonist concept, this potentially adverse effect is thought to be counterbalanced by simultaneous incretin (GIP and GLP-1) stimulation of glucose-dependent insulin secretion, which made it possible to combine glucagon receptor agonism with preserved glycemic control ^[1]. Beyond its effect on energy balance, the glucagon component may contribute to enhanced hepatic lipid oxidation, consistent with the pronounced reduction in liver fat content subsequently observed in clinical studies ^[1][7].

Molecular Engineering and Structure-Activity Relationship

Retatrutide is engineered on the GIP peptide backbone, continuing the design lineage of the GIP/GLP-1 dual agonist tirzepatide (LY3298176), whose GIP-derived backbone and engineering are described in Coskun et al. (Molecular Metabolism, 2018) ^[3]. To confer stability and the desired receptor balance, non-coded (unnatural) substitutions were introduced into the molecule: α-aminoisobutyric acid (Aib, 2-methylalanine) at positions 2 and 20, and α-methyl-leucine (2-methyl-leucine) at position 13 ^[1]. The Aib substitution near the N-terminus is an established technique that sterically protects the N-terminal dipeptide from cleavage by dipeptidyl peptidase-4 (DPP-4), a recurring motif in the engineering of incretin-class peptides ^[3].

Extension of the half-life is achieved by acylation of the lysine side chain (reportedly at position Lys17) with a C20 fatty diacid via a linker described as a γ-glutamate plus an AEEA spacer (2-[2-(2-aminoethoxy)ethoxy]acetic acid) ^[1]. This acyl chain provides reversible binding to serum albumin, slowing renal clearance and proteolysis; it is because of this that the circulating half-life is approximately 6 days, a pharmacokinetic profile compatible with once-weekly administration in studies ^[1]. An analogous albumin-binding strategy using a C20 diacid in tirzepatide yields a half-life of approximately 5 days ^[3].

Preclinical (Rodent) Efficacy

In diet-induced obese (DIO) mice, retatrutide reduced body weight with a reported ED50 of approximately 4.73 nmol/kg and improved glycemic control ^[1]. Rodent studies reported greater body weight reduction than with tirzepatide, as well as dose-dependent improvement in markers of hepatic steatosis/steatohepatitis in DIO mouse and hamster models ^[6]. These preclinical findings, together with the subsequent Phase 1 clinical pharmacology, established the compound's long, once-weekly-compatible pharmacokinetic profile ^[1][2].

Study Results

Phase 1 and Clinical Pharmacology

The early clinical pharmacology of retatrutide is described in two related publications: a single-ascending-dose (SAD) study in healthy participants, embedded within the "discovery to proof-of-concept" paper ^[1], and a separate Phase 1b multiple-ascending-dose (MAD) trial in patients with type 2 diabetes mellitus ^[2].

In the SAD study (45 healthy participants, subcutaneous administration across an ascending range of investigational doses), maximum plasma concentration was reached approximately 1–3 days after dosing, and the mean terminal half-life was approximately 5–7 days, supporting once-weekly dosing ^[1]. The Phase 1b MAD trial refined these properties: plasma concentrations, AUC(0-τ), and Cmax were approximately dose-proportional (linear) across the dose range studied; the median time to Cmax (tmax) was 12–48 hours post-dose, and the terminal half-life was approximately 6 days ^[2]. The authors concluded that this half-life "enables the achievement and maintenance of meaningful steady-state exposures following once-weekly administration" ^[2].

Pharmacodynamic persistence after a single dose was notable: in the SAD study, body weight reduction after a single subcutaneous dose was sustained through Day 43, and in the two highest-dose groups it remained statistically significant relative to placebo through approximately Day 43, consistent with the extended exposure profile ^[1].

The 12-week double-blind, placebo-controlled MAD trial enrolled 72 participants (52 received LY3437943, 5 received the comparator dulaglutide, 15 received placebo) across five ascending once-weekly dose cohorts, ranging from lower fixed doses to cohorts with stepwise titration up to the highest investigational levels ^[2]. Placebo-adjusted reductions at Week 12 reached up to −3.1 mmol/L in mean daily plasma glucose, −1.6% in HbA1c, and −8.96 kg in body weight in the highest-dose cohort studied; body weight reduction was dose-dependent across the entire dose range ^[2].

Dose-dependent changes in heart rate were already observed in Phase 1. In the SAD study, the mean change in pulse rate over 8 days from baseline increased with dose, reaching on the order of +17–25 bpm at the higher investigational doses (statistically significant versus placebo), peaking at approximately Day 4–6 and returning to baseline by Day 29–43 ^[1]. In the MAD trial, pulse rate increased in the higher-dose groups: in the three highest-dose groups, the increase was 2–13 bpm at 24 hours after the last dose and −1 to 10 bpm on average over the last 4 weeks ^[2]. Systolic blood pressure generally decreased (by up to −12 mmHg) ^[2].

Body Weight Regulation (Obesity)

The Phase 2 obesity trial (Jastreboff et al., NEJM, 2023; ClinicalTrials.gov NCT04881760) was a randomized, double-blind, placebo-controlled, parallel-group, dose-finding study in 338 adults with obesity (body mass index ≥30 kg/m², or 27 to <30 kg/m² with at least one weight-related comorbidity) without type 2 diabetes mellitus ^[4]. Participants were randomized to receive once-weekly subcutaneous retatrutide at several ascending maintenance doses or placebo for 48 weeks. Two intermediate target doses each included two cohorts with different stepwise escalation schedules, whose results were reported pooled for the corresponding maintenance levels ^[4].

The primary endpoint was percent change in body weight from baseline at Week 24 (also assessed at Week 48). The reported least-squares mean percent change in weight at Week 24 was approximately −7.2%, −12.9%, −17.3%, and −17.5% from the lowest to the highest investigational dose versus −1.6% with placebo ^[4]. At Week 48, the corresponding values were approximately −8.7%, −17.1%, −22.8%, and −24.2% versus −2.1% with placebo ^[4]. In the highest-dose group at Week 48, reportedly virtually all participants achieved a weight reduction of ≥5%, approximately 93% achieved ≥10%, and approximately 83% achieved ≥15%; approximately half achieved ≥25%, and approximately a quarter exceeded 30% ^[4]. The Week 48 weight-loss curves did not clearly plateau, suggesting the possibility of continued reduction with longer treatment ^[4][8].

Secondary cardiometabolic measures generally improved in a dose-dependent manner, including reductions in waist circumference, systolic and diastolic blood pressure, triglycerides, LDL cholesterol and total cholesterol, HbA1c, and fasting glucose and insulin at Weeks 24 and 48 ^[4]. An accompanying NEJM editorial characterized the magnitude of weight reduction as notable within the field of obesity pharmacotherapy and emphasized the need for larger and longer Phase 3 trials to establish the durability of the effect and cardiovascular safety ^[8].

Glycemic Control (Type 2 Diabetes Mellitus)

The Phase 2 type 2 diabetes mellitus trial (Rosenstock et al., The Lancet, 2023; NCT04867785) was a randomized, double-blind, double-dummy, placebo- and active-controlled (with the active comparator dulaglutide once weekly), parallel-group study conducted at 42 research and medical centers in the United States ^[5]. Of 534 individuals screened, 281 were randomized (mean age 56.2 years, standard deviation 9.7; 156 [56%] women); 237 (84%) participants completed the study, and 222 (79%) completed treatment ^[5]. Treatment groups included placebo, the active comparator dulaglutide, and retatrutide at several ascending maintenance doses with different escalation schedules (including, for intermediate doses, a comparison of slower versus faster titration) ^[5].

The primary endpoint was change in HbA1c from baseline to Week 24; secondary endpoints included change in HbA1c and body weight at Week 36 ^[5]. The least-squares mean change in HbA1c at Week 24 increased with dose, from approximately −0.43% at the lowest investigational dose to approximately −2.02% at the highest, versus −0.01% with placebo and −1.41% with the comparator dulaglutide ^[5]. The reduction was significantly greater than placebo (p<0.0001) for all retatrutide groups except the lowest investigational dose, and higher doses exceeded the active comparator dulaglutide ^[5].

The change in body weight at Week 36 was dose-dependent, increasing from approximately −3.19% at the lowest investigational dose to approximately −16.94% at the highest, versus −3.00% with placebo and −2.02% with the comparator dulaglutide; intermediate and higher doses of retatrutide showed significantly greater weight reduction than both placebo and dulaglutide ^[5]. The investigators concluded that in this population, retatrutide provided clinically meaningful improvement in glycemia and dose-dependent body weight reduction, with a safety profile consistent with GLP-1 and GIP/GLP-1 agonists ^[5].

Hepatic Steatosis (MASLD)

The effect of retatrutide on liver fat content was analyzed in detail in a separate Phase 2a publication devoted to metabolic dysfunction-associated steatotic liver disease (Sanyal et al., Nature Medicine, 2024) ^[7]. This work represents an analysis of a pre-specified subgroup of participants from the obesity trial ^[4] who had raised baseline liver fat content (≥10% by magnetic resonance imaging (MRI)-proton density fat fraction, MRI-PDFF); this subgroup included 98 individuals distributed between placebo and several ascending doses of retatrutide ^[7]. Mean relative reductions in liver fat content at Week 24 were approximately −42.9%, −57.0%, −81.4%, and −82.4% from the lowest to the highest investigational dose versus +0.3% with placebo ^[7]. Normalization of liver fat content (<5%) was achieved by approximately 27%, 52%, 79%, and 86% in the ascending dose groups versus 0% with placebo ^[7].

Body Composition

Changes in body composition during retatrutide treatment were assessed in a pre-specified substudy of the Phase 2 type 2 diabetes mellitus trial using dual-energy X-ray absorptiometry (DXA) (Coskun et al., The Lancet Diabetes & Endocrinology, 2025) ^[10]. This substudy included 189 participants. The reduction in fat mass from baseline at Week 36 was dose-dependent and was approximately 4.9%, 15.2%, 26.1%, and 23.2% from the lowest to the highest investigational dose versus approximately 4.5% with placebo and 2.6% with the comparator dulaglutide ^[10]. The proportion of lean (muscle) mass loss within total weight reduction was comparable to that reported for other weight-loss agents ^[10].

Tolerability and Adverse Events

Across all Phase 1–2 clinical trials, the adverse event profile was predominantly gastrointestinal, dose-dependent, and mostly mild-to-moderate, consistent with the pharmacology of the incretin class ^[1][2][4][5].

In the Phase 1b MAD trial, treatment-emergent adverse events were reported in 63% (LY3437943), 60% (dulaglutide), and 54% (placebo); the most common were gastrointestinal disorders, predominantly diarrhea, nausea, and vomiting, and the proportion of treatment-related events increased with dose ^[2]. In the highest-dose cohort studied, the burden of gastrointestinal events was greatest (nausea 50%, diarrhea 50%, vomiting 25%), in contrast to substantially lower rates in the low-dose cohorts ^[2]. Most gastrointestinal events were mild-to-moderate and resolved within approximately 10 days of onset despite continued dosing ^[2].

In the Phase 2 obesity trial, adverse events were predominantly gastrointestinal (nausea, diarrhea, vomiting, constipation), dose-dependent, and mostly mild-to-moderate; discontinuation due to adverse events occurred in approximately 6–16% of retatrutide recipients across the dose groups ^[4]. A dose-dependent increase in heart rate was observed, peaking around Week 24 (on the order of a few beats per minute at higher doses) and subsequently decreasing through Week 48; no arrhythmia signal or drug-related serious cardiovascular events were reported in Phase 2 ^[4].

In the Phase 2 type 2 diabetes mellitus trial, the most common adverse events were likewise gastrointestinal (nausea, diarrhea, vomiting, and constipation), predominantly mild-to-moderate, occurring mainly during dose escalation and more frequently at higher doses ^[5]. Such events were reported in 67 (35%) of 190 participants in the retatrutide groups (ranging from approximately 13% at the lowest investigational dose to 50% in one of the higher-dose groups with faster titration) ^[5]. No cases of severe hypoglycemia or deaths were recorded during the study ^[5].

Phase 3 Program

Following the Phase 2 trials, retatrutide advanced to a large-scale Phase 3 clinical trial program ^[11]. The first published Phase 3 trial, TRANSCEND-T2D-1 (Bajaj et al., The Lancet, 2026; NCT06354660), was a 40-week double-blind, placebo-controlled monotherapy trial in 537 adults with type 2 diabetes mellitus inadequately controlled by diet and exercise alone ^[9]. Participants received once-weekly retatrutide at several ascending doses or placebo; the reported change in HbA1c at Week 40 was approximately −1.69%, −1.86%, and −1.94% from the lower to the higher investigational dose versus −0.81% with placebo, and weight reduction reached approximately 17% at the higher dose ^[9]. The broader Phase 3 program, named TRIUMPH, encompasses trials in obesity and related conditions (including obstructive sleep apnea and knee osteoarthritis) under a single-protocol design with nested sub-protocols, as well as a separate cardiovascular and renal outcomes trial; its design is described in Giblin et al. (Diabetes, Obesity and Metabolism, 2026) ^[11]. As of the cited publications, some of these trials were still ongoing, and their final results on long-term efficacy and safety had not yet been fully published ^[11].

Pharmacokinetics and Stability (Research Context)

The pharmacokinetic profile of retatrutide is determined by its extended-action structure. The terminal half-life is approximately 6 days (reported as approximately 5–7 days in the single-ascending-dose study) ^[1][2]. Cmax and AUC(0-τ) were approximately dose-proportional (linear) across the dose range studied in the Phase 1b MAD trial ^[2]. The median time to maximum concentration (tmax) was 12–48 hours post-dose in the MAD trial, whereas in the SAD study Cmax was reached approximately 1–3 days post-dose ^[1][2].

The extended exposure is a direct consequence of molecular engineering: acylation with a C20 fatty diacid provides reversible binding to serum albumin, which slows renal clearance and proteolysis and underlies the approximately 6-day half-life ^[1]. The compound's molar mass is approximately 4731 Da. It is this pharmacokinetics, compatible with once-weekly administration, that enabled the achievement and maintenance of steady-state exposures in clinical trials ^[2].

In the research context, retatrutide is supplied as a lyophilized (freeze-dried) powder. These notes relate solely to the physicochemical properties of the compound and do not contain any guidance regarding preparation or administration to humans.

Research Status and Handling

Retatrutide (LY3437943) is an investigational compound; all data presented above derive from published preclinical work and Phase 1–3 clinical trials ^{[1][2][4][5][7][9]}. The sequence of publications includes the "discovery to proof-of-concept" characterization (Cell Metabolism, 2022) ^[1], the Phase 1b clinical pharmacology (The Lancet, 2022) ^[2], and separate Phase 2 trials in obesity (NEJM, 2023) ^[4], in type 2 diabetes mellitus (The Lancet, 2023) ^[5], and in steatotic liver disease (Nature Medicine, 2024) ^[7]. The preclinical design lineage builds on the GIP-derived backbone of tirzepatide (Molecular Metabolism, 2018) ^[3] and on rodent models describing the compound's metabolic effects ^[6]. An accompanying NEJM editorial emphasized the need for longer and larger Phase 3 trials to establish the durability of the effect and cardiovascular safety ^[8]. As of the cited publications, the Phase 3 program has already begun: the first Phase 3 result (TRANSCEND-T2D-1) has been published ^[9], while the broader TRIUMPH program, including the cardiovascular and renal outcomes trial, was ongoing at the time of writing ^[11].

All dose levels presented in this article describe the design of published preclinical and clinical studies and do not constitute guidance for use. This article is a neutral scientific reference overview intended solely for research and informational purposes and does not constitute medical, therapeutic, or dosing advice.